Press Release
March 22, 2021

Aura Biosciences Completes $80 Million Financing Round

The Life Sciences team advised Aura Biosciences on the closing of its oversubscribed $80 million financing. The financing was led by Matrix Capital Management and Surveyor Capital with participation from new investors, including Rock Springs Capital, Adage Capital Management LP and Velosity Capital. Existing investors Medicxi, Advent Life Sciences, Lundbeckfonden Ventures, Arix Bioscience, Chiesi Ventures, Ysios Capital and Columbus Venture Partners also participated in the round.


The company plans to use the proceeds from this financing to advance the clinical development of its VDC technology platform, including the pivotal Phase 3 program for AU-011, Aura’s lead candidate in development for the first line treatment of choroidal melanoma, and ongoing research for additional programs in ocular oncology, as well as expanding the VDC technology into bladder cancer, the first non-ophthalmic solid tumor indication.


Aura Biosciences is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity.


The Goodwin team was led by Danielle LauzonStuart Cable, Stephanie Richards, Dan Hughes and Karin Yoo.


For additional details on the financing round, please read the press release.